Written Question·Department of Health and Social Care·UIN 3107
Trastuzumab Deruxtecan
Tabled: 30 August 2024
Answered: 9 September 2024
Question
Daisy Cooper
Liberal Democrat — St Albans
To ask the Secretary of State for Health and Social Care, if he will make representations to (a) Daiichi Sankyo and (b) AstraZeneca following the decision by NICE not to recommend Enhertu as a cost effective treatment for advanced stage breast cancer.
Answer
Karin SmythDecisions on whether new medicines should be routinely funded by the National Health Service in England are taken by the National Institute for Health and Care Excellence (NICE), on the basis of an evaluation of a treatment’s costs and benefits. The NICE’...
ⓘ
This is an extract from the Parliament API. Search the full answer on Parliament.uk (UIN 3107) →